Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Duodenoscope-Makers Ordered By FDA To Conduct Sec. 522 Postmarket Surveillance Studies

This article was originally published in The Gray Sheet

Executive Summary

FDA orders three duodenoscope manufacturers – Olympus America, Fujifilm Medical Systems and Hoya Corp.'s Pentax Life Care Division – to conduct postmarket surveillance studies to better understand how the scopes are being reprocessed and how to reduce the risk of patient infection. The firms told "The Gray Sheet" that they will comply with the agency's request.

Advertisement

Related Content

Califf Sets Departure From US FDA; Ostroff May Become Interim Leader
MDR Reporting: FDA Embraces Adverse Event Summaries Under MDUFA IV, But Flouts Similar FDAAA Mandate
FDA '522' Guidance: 15-Month Deadline To Comply With Postmarket Order
FDA Drafts Plan To Publicize 'Emerging Signals' Of Device Risks
Postmarket Device Surveillance Reforms Raised At Califf Confirmation Hearing
FDA Orders Custom Ultrasonics To Recall All Endoscope Reprocessors
Latest FDA Crackdown On Duodenoscope Makers Includes Warning Letters, 510(k) Status Alerts
Added Duodenoscope Reprocessing Steps Will Reduce Risks, FDA Says
FDA Advisors Call For New Cleaning Methods, Sterilization For Duodenoscopes
FDA Lays Down Strict Disinfection Guidance In Wake Of Scope Incidents

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT034276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel